The cholinergic septo-hippocampal pathway is critically involved in
learning and memory functions of the hippocampus and a likely substrate
for the neurotoxic effects of low-level lead (Pb) exposure in children.
We observed that exposure of neonatal rats to low levels of lead causes
selective reduction in ontogenic expression of cholinergic marker enzyme
cholineacetyltransferase (ChAT) and muscarinic receptors in the septum
without inducing similar changes in the hippocampus. This implicates the
cholinergic septo-hippocampal neurons as a particularly vulnerable target
for the developmental insult by inorganic lead. In this proposal we will
investigate in detail, the mechanism and functional consequences of
lead's effects on the septa) cholinergic cells. (1) Receptor radioligand
binding to septal homogenates from control and lead-exposed neonatal rats
will be used to determine the developmental time course of the Pb-induced
reduction in muscarinic receptors and its persistence into adulthood; (2)
Receptor subtype-selective radioligand binding and a combination of
receptor autoradiography and ChAT immunocytochemistry in brain sections
and/or dissociated septal cultures will be used to determine which
muscarinic receptor subtype(s) are reduced and establish their
localization to the cholinergic neurons; (3) a hypothesis that Pb
interferes with the regulation of receptor expression by nerve growth
factor (NGF) will be tested by examining the interaction between NGF and
Pb on the expression of muscarinic receptors in dissociated septal
cultures: (a) 125I-NGF binding to dissociated cells will be used to
determine if lead interferes with binding and uptake of NGF by the target
neurons and (b) receptor hybridization will be used to determine if NGF
induces and Pb inhibits the induction of receptor subtypes-specific mRNA;
(4) Whole cell patch-clamp recording from dissociated septal neurons in
culture will be used to determine the effect of Pb exposure on the
development of chemosensitivity to ACh in the septal cholinergic neurons
and test Pb's effect on the electrophysiological characteristics of these
neurons; specifically, we will test a hypothesis that Pb modifies the
characteristic rhythmic, pacer-like firing properties of cholinergic
cells by (a) attenuating muscarinic abbreviation of postspike
afterhyperpolarization (AHP) , (b) altering Ca conductances, and (c)
modifying the outward Ca-dependent potassium currents in the Pb-exposed
cells. The phenotype of the cells will be identified after recordings by
immunocytochemical staining with anti-ChAT antibodies. These experiments
should provide new insights into the neurobiology of the cholinergic
septo-hippocampal neurons and the extent to which alterations in their
chemosensitive and electrical membrane properties might be involved in
Pb-induced behavioral toxicity.
National Institute of Environmental Health Sciences
CFDA Code
DUNS Number
041064767
UEI
DZ4YCZ3QSPR5
Project Start Date
01-April-1993
Project End Date
31-March-1996
Budget Start Date
01-April-1994
Budget End Date
31-March-1995
Project Funding Information for 1994
Total Funding
$217,222
Direct Costs
$142,495
Indirect Costs
$74,727
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Environmental Health Sciences
$217,222
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01ES006365-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01ES006365-02
Patents
No Patents information available for 5R01ES006365-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01ES006365-02
Clinical Studies
No Clinical Studies information available for 5R01ES006365-02
News and More
Related News Releases
No news release information available for 5R01ES006365-02
History
No Historical information available for 5R01ES006365-02
Similar Projects
No Similar Projects information available for 5R01ES006365-02